Welcome to
Pint Pharma website

Enabling Latin American population with life-altering conditions to live better lives by providing early and efficient access to innovative technologies.

Therapeutic Areas

OUR ASPIRATION: To become a leading LatAm biotech company delivering innovative treatments to patients with cancers, rare diseases and other specialty conditions

Pint Global

 

 

>> Our subsidiaries 

 

 

Partners

Located in the heart of Europe, Pint Pharma is well situated to service our global partners through our operational teams in Switzerland and Austria. We pride ourselves in providing exceptional expertise and know-how of the Latin American pharmaceutical industry, and strive to provide best-in-class treatment and service to the patient population through strategic alliances with our global business partners..

All Partners
Amicus

Amicus

Eisai

Eisai

Gebro

Gebro

Onxeo

Onxeo

Pharma Mar

Pharma Mar

Puma Biotechnology

Puma Biotechnology

Shire

Shire

News

.

 

Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America

17 August 2018

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced it has entered into an exclusive license agreement with Pint Pharma for the commercialization of Beleodaq® (belinostat), Onxeo’s pan-HDAC inhibitor for PTCL (peripheral T-cell lymphoma), in key South American countries.

Read more

ARIAD Announces Distribution Agreements for Iclusig® in Latin America and the Middle East/North Africa

17 August 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (ARIAD; NASDAQ:ARIA) today announced that it has completed two distribution agreements for Iclusig® (ponatinib) outside of the United States. In Latin America, ARIAD and Pint Pharma International S.A., a company focused on innovative treatments for patients in Latin America with cancer, rare diseases, and genetic disorders,

Read more

Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America

17 August 2018

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pint Pharma International S.A., a company focused on innovative treatments for patients in Latin America with cancer, rare diseases, and genetic disorders, have entered into an agreement for Pint Pharma to commercialize NERLYNX® (neratinib)

Read more

Onconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin America

17 August 2018

NEWTOWN, Pa., March 05, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS),

Read more

Pharmacovigilance

Pint Pharma has its own pharmacovigilance system that monitors the safety and efficacy of our products when our customers are using them.

If a side effect is experienced, please write an email to: